免疫检查点抑制剂治疗癌症患者中的免疫相关脱发(斑秃与全秃)
本文首次系列描述免疫检查点抑制剂(ICI)相关斑秃(AA)的临床病理特征,包括首例抗PD-L1治疗诱导的AA,并回顾文献。从临床识别4例接受ICI治疗的癌症患者出现部分或完全脱发,其中3例为AA、1例为全秃;2例经局部、口服或皮损内治疗缓解,1例停药后缓解,所有再生毛发均呈白发症。1例伴甲营养不良。
要点
- 所有毛发再生均出现白发症(poliosis),提示毛发相关irAE的独特表现。
- 管理包括局部/口服/皮损内治疗或停药,需重视治疗前咨询与生活质量维护。
核心结论
- ICI治疗可诱发斑秃(AA)和全秃,首例抗PD-L1诱导AA被报告,毛发再生常伴白发症。
研究设计与样本
- 从临床识别4例接受ICI治疗的癌症患者出现部分或完全脱发,回顾病史与临床病理特征并复习文献。
主要发现
- 4例中3例(75%)为斑秃,1例为全秃;2例经局部、口服或皮损内治疗缓解,1例停药后缓解。
- 所有再生毛发均表现为白发症(poliosis),1例伴甲营养不良。
关键数值与推荐
- 4例中3例(75%)为斑秃,1例为全秃。
临床怎么用
- 认识和管理毛发相关irAE对治疗前咨询和干预重要,有助于维持患者最佳健康相关生活质量。
局限性
- 样本量小(4例),为病例系列和文献回顾,证据等级有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cytotoxic T-lymphocyte-associated protein-4, programmed cell death protein and programmed cell death protein ligand 1 monoclonal antibodies (immune checkpoint inhibitors), are used to treat various malignancies. Their mechanism of action involves the inhibition of negative regulators of immune activation, resulting in immune-related adverse events (irAEs) including endocrinopathies, pneumonitis, colitis, hepatitis and dermatological events. Dermatological irAEs include maculopapular rash, pruritus, vitiligo, blistering disorders, mucocutaneous lichenoid eruptions, rosacea and the exacerbation of psoriasis. Alopecia secondary to immune checkpoint inhibitors has been reported in 1·0-2·0% of treated patients. Our objective is to characterize for the first time the clinicopathology of patients with alopecia areata (AA) secondary to immune checkpoint inhibitors, including the first report of anti-PD-L1 therapy-induced AA, and review of the literature. Four cases of patients who developed partial or complete alopecia during treatment with immune checkpoint inhibitors for underlying cancer were identified from our clinics. Methods include the review of the history and clinicopathologic features. Three patients (75%) had AA and one had universalis. Two patients had a resolution after topical, oral or intralesional therapies and one had a resolution after immunotherapy was discontinued; all regrown hair exhibited poliosis. One of the four patients had coincident onychodystrophy. This report describes a series of four patients who developed partial or complete alopecia (i.e. areata and universalis) during treatment with immune checkpoint inhibitor therapies for cancer. The recognition and management of hair-related irAEs are important for pretherapy counselling and interventions that contribute to maintaining optimal health-related quality of life in patients.
引用
- Zarbo A, Belum VR, Sibaud V, et al. Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors. Br J Dermatol. 2017. PMID: 27943234. doi:10.1111/bjd.15237
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。